Supporting information for

A simple and traceless solid phase method simplifies the assembly of large peptides and the access to challenging proteins

N. Ollivier, R. Desmet, H. Drobecq, A. Blanpain, E. Boll, B. Leclercq, A. Mougel, J. Vicogne, O. Melnyk*

UMR CNRS 8161 CNRS, Université de Lille, Institut Pasteur de Lille, 1 rue du Pr Calmette, 59021 Lille Cedex, France.

Corresponding author:
Dr Oleg Melnyk, E-mail: oleg.melnyk@ibl.cnrs.fr
Web site: http://olegmelnyk.cnrs.fr

Phone: +33 (0)3 20 87 12 14; ORCID
Cent Nat de la Recherche Scientifique (CNRS)
Institut de Biologie de Lille
1 rue du Pr Calmette, CS 50447, 59021 Lille cedex, France
Content

1. General methods ..........................................................................................................................................4

2. Synthesis of AcA peptides 4 on the solid phase (Scheme 1A, method A) .............................................5
   2.1 Characterization of N-acetoacetyl peptide 4a ......................................................................................6
   2.2 Characterization of N-acetoacetyl peptide 4b ...................................................................................7
   2.3 Characterization of N-acetoacetyl peptide 4c ...................................................................................9
   2.4 Characterization of N-acetoacetyl peptide 4d ..................................................................................10
   2.5 Characterization of N-acetoacetyl peptide 4e ..................................................................................11
   2.6 Characterization of N-acetoacetyl peptide 4f ..................................................................................12
   2.7 Characterization of N-acetoacetyl peptide 8 ..................................................................................16

3. Synthesis of N-acetoacetyl peptide 7 by NCL using acetoacetyl thioester 6 (Scheme 1, method B) ..............................................................................................................................................................18
   3.1 Characterization of N-acetoacetyl peptide 7 ....................................................................................18

4. Synthesis of AcAO peptide 9 and 10a-d ..................................................................................................19
   4.1 Characterization of AcAO peptide 9 .................................................................................................20
   4.2 Characterization of AcAO peptide 10a .............................................................................................28
   4.3 Characterization of AcAO peptide 10b .............................................................................................29
   4.4 Characterization of AcAO peptide 10c .............................................................................................30
   4.5 Characterization of AcAO peptide 10d .............................................................................................32

5. Synthesis of PEGA resin 11 ..................................................................................................................33
   5.1 Synthesis of Fmoc aminooxyacetic acid ............................................................................................33
   5.2 Characterization of Fmoc aminooxyacetic acid .................................................................................33
   5.3 Preparation of resin 11 .......................................................................................................................34

6. Immobilization of AcA peptide 4b ..........................................................................................................34
   6.1 TFA cleavage leading to peptide 14b .................................................................................................34
   6.2 Characterization of peptide 14b .........................................................................................................35

7. Kinetic studies of the transoximation/rearrangement sequence: effect of the pH in the presence of aniline ..................................................................................................................................................................36

8. Optimization of the cleavage protocol to minimize the formation of hydroxamic acid derivatives from Gln and Asn ..................................................................................................................................................37
   8.1 Influence of the pH (cleavage method A at pH 4.3, 3.5 and 3.0) .....................................................37
   8.2 Influence of additives: acetamide (cleavage method A at pH 3.0) ...................................................38
   8.3 Influence of aniline concentration on the rate of cleavage ..............................................................38
8.4. Influence of hydroxylamine concentration on the rate of cleavage

9. Synthesis of ALKEPVHGA-SEA^{off} peptide 15b

9.1 Cleavage method A

9.2 Characterization of peptide 15b (cleavage method A)

9.3 Cleavage method B

9.4 Characterization of peptide 15b (cleavage method B)

10. Solid phase synthesis of peptide 17

10.1 Cleavage method A

10.2 Characterization of peptide 17 (cleavage method A)

10.3 Cleavage method B

10.4 Characterization of peptide 17 (cleavage method B)

11. Solid phase synthesis of peptide 18 (cleavage method A)

11.1 Characterization of protein 18 (cleavage method A)

11.2 Folding of peptide 18 into HGF K1 domain

11.3 Characterization of HGF K1 domain

11.4 Biological assays. K1 domain

11.5 Proteomic analysis of synthetic K1 domain

12. Total synthesis of biotinylated NK1 protein

12.1 One-pot synthesis of linear polypeptide NK1-B

12.2 Folding of NK1-B polypeptide

12.3 Biological activity

13. Peptide purification by covalent capture

13.1 Introduction

13.2 Protocol and monitoring by LC-MS

13.2 Characterization of peptide 25

14. References
1. General methods

Reagents and solvents

2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium fluorophosphate (HBTU) and N-Fmoc protected amino acids were obtained from Iris Biotech GmbH. Side-chain protecting groups used for the amino acids were Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OrBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OrBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Cys(SrBu)-OH or Fmoc-Cys(Trt)-OH. Synthesis of bis(2-sulfanylethyl)aminotrityl polystyrene (SEA PS) resin was carried out as described elsewhere. Rink-PEG-PS resin (NovaSyn TGR) resin was obtained from Novabiochem. 4-Mercaptophenylacetic acid (MPAA), 3-mercaptopropionic acid (MPA), triethyl(2-carboxyethyl)phosphine hydrochloride (TCEP), triisopropylsilane (TIS), dimethyl sulfide (DMS), guanidine hydrochloride were purchased from Sigma-Aldrich. All other reagents were purchased from Acros Organics or Merck and were of the purest grade available.

Peptide synthesis grade N,N-dimethylformamide (DMF), dichloromethane (CH₂Cl₂), diethylether (Et₂O), acetonitrile (CH₃CN), heptane, LC–MS-grade acetonitrile (CH₃CN, 0.1% TFA), LC–MS-grade water (H₂O, 0.1% TFA), N,N-diisopropylethylamine (DIEA), acetic anhydride (Ac₂O) were purchased from Biosolve and Fisher-Chemical. Trifluoroacetic acid (TFA) was obtained from Biosolve. Water was purified with a Milli-Q Ultra Pure Water Purification System.

Analyses and purifications

Products were characterized by analytical LC–MS (Waters 2695 LC/ZQ 2000 quadripole) on a reverse phase column XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm) at 30 °C using a linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H₂O; eluent B = 0.1% TFA in CH₃CN/H₂O: 4/1 by vol) or on a Zorbax 300SB-C3 (3.5 µm, 300 Å, 4.6 × 150 mm) at 50 °C using a linear gradient of 0-50% of eluent D in eluent C over 30 min at a flow rate of 1 mL/min (eluentC = 0.1% formic acid in H₂O; eluent D = 0.1% formic acid in CH₃CN/H₂O: 4/1 by vol). The column eluate was monitored by UV at 215 nm and by evaporative light scattering (ELS, waters 2424). The peptide masses were measured by on-line LC–MS: Ionization mode: ES+, m/z range 350–2040, capillary voltage 3 kV, cone voltage 30 V, extractor voltage 3 V, RF lens 0.2 V, source temperature 120 °C, dessolvation temperature 350 °C. Calculated masses were based on average isotope composition.

MALDI-TOF mass spectra were recorded with a Bruker Autoflex Speed using alpha cyano 4-hydroxycinnaminic acid, sinapinic acid or 2,5-dihydroxybenzoic acid (DHB) as matrix. The observed m/z corresponded to the monoisotopic ions, unless otherwise stated.
Preparative reverse phase HPLC of crude peptides were performed with a preparative HPLC Waters system using a reverse phase column XBridge BEH300 Prep C18 (5 µm, 300 Å, 10 × 250 mm) and appropriate linear gradient of increasing concentration of eluent B in eluent A (flow rate of 6 mL/min). Selected fractions were then combined and lyophilized.

2. Synthesis of AcA peptides 4 on the solid phase (Scheme 1A, method A)

AcA peptides were produced by Fmoc-SPPS as described elsewhere.\(^1\)

**Typical experimental procedures**

**Coupling of N-acetoacetyl group (AcA) on the solid phase**

After elongation of the peptide on SEA PS resin and terminal Fmoc deprotection (0.25 mmol scale), diketen (10 equiv, 191.6 µL) or N-hydroxysuccinimidyl acetoacetate (10 equiv, 497.9 mg) and N-methylmorpholine (5 equiv, 137.4 µL) were dissolved in the minimal volume of DMF and the resulting solution was added to the peptidyl resin. After stirring 30 min, the resin was washed with DMF (3 × 2 min). The completion of the acylation step was verified using the Kaiser test for primary amines. Then, resin was washed with DCM (3 × 2 min), diethyl ether (3 × 2 min), and dried in vacuo.

**Final peptide deprotection and cleavage**

Peptides were deprotected and cleaved from the resin using TFA/DMS/thioanisol/3,4-difluorothiophenol/water: 90/2.5/2.5/2.5/2.5 by vol for 1 h (10 mL for 0.10 mmol of peptidyl resin, 25 mL for 0.25 mmol of peptidyl resin). The crude peptides were precipitated in cold diethyl ether/heptane: 1/1 by vol (200 mL for 0.1 mmol of peptidyl resin, 500 mL for 0.25 mmol of peptidyl resin), solubilized in deionised water and lyophilized.

**Oxidation (SEA\(^{on}\) → SEA\(^{off}\)) and purification**

The crude peptide (59.62 µmol) was dissolved in 50 mM MES buffer pH=6/DMSO 1/1 by vol (8.06 mL). The solution was stirred overnight at rt. The reaction medium was then diluted with eluent A (final volume 80 mL) and purified by RP-HPLC as described in the general procedure (eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 by vol containing 0.1% TFA, 30 °C, detection at 215 nm).

| Table S 1. Synthesis of AcA peptides 3a-e (method 1). |
|-----------------|---------|-----------------|-----------------|
| peptide | scale (mmol) | crude yield | HPLC purified (yield) |
| 4a | 0.1 mmol | 100 mg (74.7%) | 44.4 mg (33%) |
| 4b | 0.1 mmol | 107.1 mg (79.2%) | 46 mg (34%) |
| 4c | 0.1 mmol | 107.4 mg (77%) | 49.8 mg (35.8%) |
2.1 Characterization of N-acetoacetyl peptide 4a

Figure S 1. LC-MS analysis of peptide 4a. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1108.53, obs 1108.7.
2.2 Characterization of N-acetoacetyl peptide 4b
Figure S 3. LC-MS analysis of peptide 4b. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH3CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]+ m/z calcd. (monoisotopic) 1122.54, obs 1122.6.

Figure S 4. MALDI-TOF analysis of peptide 4b. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, [M+H]+ calcd. (monoisotopic) 1122.54, found 1122.5.
2.3 Characterization of N-acetoacetyl peptide 4c

Figure S 5. LC-MS analysis of peptide 4c. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH3CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]+ m/z calcd. (monoisotopic) 1164.59, obs 1165.0.

Figure S 6. MALDI-TOF analysis of peptide 4c. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, [M+H]+ calcd. (monoisotopic) 1164.59, found 1164.3.
2.4 Characterization of N-acetoacetyl peptide 4d

Figure S 7. LC-MS analysis of peptide 4d. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1355.53, obs 1355.7.
**Figure S 8.** MALDI-TOF analysis of peptide **4d.** Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, $[\text{M+H}]^+$ calcd. (monoisotopic) 1355.53, found 1355.4.

### 2.5 Characterization of N-acetoacetyl peptide **4e**

**Figure S 9.** LC-MS analysis of peptide **4e.** LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. $[\text{M+H}]^+$ m/z calcd. (monoisotopic) 674.31, obs 674.4.
Figure S 10. MALDI-TOF analysis of peptide 4e. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, [M+H]+ calcd. (monoisotopic) 674.31, found 674.3.

2.6 Characterization of N-acetoacetyl peptide 4f
Figure S 11. LC-MS analysis of peptide 4f. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). The peak at 19.83 min corresponds to the thioester form of the SEA$^m$ group. The peak at 21.12 min corresponds to the amide form of the SEA$^m$ group. MS trace. [M+3H]$^{3+}$ m/z calcd. (mean) 1178.42, obs 1178.3, [M+4H]$^{4+}$ m/z calcd 884.06, obs 883.6.
Intensity (AU)

1500
1250
1000
750
500
250
0

1460.84
1875.14

[M+H]^+
3531.02

[m/z]

Intensity (AU)

1500
1250
1000
750
500
250
0

[M+H]^+
3531.02

[M+Na]^+
3553.05

[m/z]
Figure S 12. MALDI-TOF analysis of peptide 4f. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, [M+H]+ calcd. (monoisotopic) 3530.87, found 3531.02.

Figure S 12 shows that peptide 4f decomposes during the ionization process according to a McLafferty mechanism. This is a typical signature of O-acyl isopeptides that has been discussed previously by us. The formed enamine products hydrolyze into β-ketoamides as shown below.
Figure S 13. O-acyl isopeptides decompose in the gas phase during the MALDI-TOF desorption/ionization process according to a McLafferty rearrangement. Ions presumably formed during the analysis of peptide 4f.

2.7 Characterization of N-acetoacetyl peptide 8
Figure S 14. LC-MS analysis of peptide 8. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH₃CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]⁺ m/z calcd. (monoisotopic) 1004.55, obs. 1004.7.

Figure S 15. MALDI-TOF analysis of peptide 8. Matrix, 2,5-dihydroxybenzoic acid (DHB), positive detection mode, [M+H]⁺ calcd. (monoisotopic) 1004.55, found 1004.6.
3. Synthesis of N-acetoacetyl peptide 7 by NCL using acetoacetyl thioester 6 (Scheme 1, method B)

0.1 M phosphate buffer pH 7 was degassed during 30 minutes. 6 M Gn.HCl (2.86 g) was dissolved in this buffer (2.950 mL) to give a final volume of 5 mL and added on 4-mercaptophenylacetic acid (168.3 mg, ~0.2 M final concentration). 6 M NaOH (290 µL) was added to adjust the pH to 7-7.5. Peptide H-C(StBu)IIGKGRSYKTVSITKSGIK-SEA<sub>off</sub> (19.8 mg, 6.43 µmol) was dissolved in this solution (1.5 mL). This last solution was added to AcAMP (1.47 mg, 7.72 µmol). The reaction was placed under inert atmosphere at 37°C overnight. The reaction mixture was then acidified with glacial acetic acid (400 µL) and diluted with water (8 mL final volume). Extractions with diethyl ether were done to remove 4-mercaptophenylacetic acid before purification by RP-HPLC (eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 containing 0.1% TFA, 30°C, detection at 215 nm, 6 mL/min, 0 to 20% eluent B in 5 min, then 20 to 40% eluent B in 60 min, C18XBridge column) to give 11.9 mg of peptide 7 (62.4%).

3.1 Characterization of N-acetoacetyl peptide 7

![Intensity (light scattering, AU)](image)

Figure S 16. LC-MS analysis of peptide 7. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH<sub>3</sub>CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 µm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace: [M+2H]<sup>2+</sup> m/z calcd (mean). 1199.98, obs. 1199.6, [M+3H]<sup>3+</sup> m/z calcd. 800.32, obs.800.0, [M+4H]<sup>4+</sup> m/z calcd.600.49, obs. 600.3.
4. Synthesis of AcAO peptide 9 and 10a-d

A typical protocol is illustrated with the synthesis of AcAO peptide 9

Gn.HCl (573.5 mg) was dissolved in 0.1 M acetate buffer pH 4.4 (590 µL). 6 M NaOH (3 µL) was added to adjust the pH to 4.8. Then peptide AcA-ALKEPVHGA-NH₂ 8 (9.99 mg, 8.11 µmol) was dissolved in this solution (final volume ~600 µL). Aminooxyacetic acid (884 µg, 8.11 µmol) was dissolved in the same solution above (210.8 µL) and added to the peptide solution. The measured pH was 4.18. The reaction was stirred at 37 °C. After 5 hours, the reaction mixture was diluted to 8 mL with eluent A and purified by RP-HPLC (preparative column XBridge BEH300 Prep C18, 5 µm, 300 Å, 10 × 250 mm) to give 7.47 mg of AcAO peptide 9 (70.6%).
Table S 2. Synthesis of AcAO peptides 8 and 10a-d.

| starting AcA peptide (mass) | AcAO peptide (mass, isolated yield) |
|----------------------------|-------------------------------------|
| 8  (9.99 mg)               | 9  (7.47 mg, 70.6%)                 |
| 4a (10.64 mg)              | 10a (10.1 mg, 90.2%)                |
| 4b (29.9 mg)               | 10b (26.4 mg, 84%)                  |
| 4c (10.22 mg)              | 10c (9.7 mg, 90.2%)                 |
| 4d (6.41 mg)               | 10d (4.64 mg, 69.3%)                |

4.1 Characterization of AcAO peptide 9

Figure S 18. LC-MS analysis of peptide 9. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH₃CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]+ m/z calcd. (monoisotopic) 1077.57, obs 1077.6.
**Figure S 19.** MALDI-TOF analysis of peptide 9. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1077.57, found 1077.6.

**NMR analysis of AcAO peptide 9**

**Figure S 20.** $^1$H NMR spectrum (300.0 MHz, H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.
Figure S 21. $^{13}$C NMR spectrum (75 MHz, H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.
Figure S 22. $^1$H-$^1$H COSY spectrum (H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.
Figure S 23. $^1$H-$^{13}$C HSQC spectrum ($\text{H}_2\text{O}/\text{D}_2\text{O}$ 90/10 by vol) for AcAO peptide 9.
Figure S 24. $^1$H-$^1$H DIPSI spectrum (TOCSY) (H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.

Figure S 25. $^1$H-$^1$H NOESY spectrum (TOCSY) (H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.
Figure S 26. $^1$H-$^{13}$C HMBS spectrum (TOCSY) ($\text{H}_2\text{O}/\text{D}_2\text{O}$ 90/10 by vol) for AcAO peptide 9.
Figure S 27. HMBC/HSCQ spectrum (75 MHz, H$_2$O/D$_2$O 90/10 by vol) for AcAO peptide 9.
4.2 Characterization of AcAO peptide 10a

Figure S 28. LC-MS analysis of peptide 10a. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 µm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1181.54, obs 1181.8.
Figure S 29. MALDI-TOF analysis of peptide 10a. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]^+ calcd. (monoisotopic) 1181.54, found 1181.6.

4.3 Characterization of AcAO peptide 10b

Figure S 30. LC-MS analysis of peptide 10b. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]^+ m/z calcd. (monoisotopic) 1195.56, obs 1195.7.
Figure S 31. MALDI-TOF analysis of peptide 10b. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1195.56, found 1195.5.

4.4 Characterization of AcAO peptide 10c
Figure S 32. LC-MS analysis of peptide 10c. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 µm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1237.61, obs 1237.8.

Figure S 33. MALDI-TOF analysis of peptide 10c. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1237.61, found 1237.7.
4.5 Characterization of AcAO peptide 10d

**Figure S 34.** LC-MS analysis of peptide 10d. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1428.65, obs 1428.7.

**Figure S 35.** MALDI-TOF analysis of peptide 10d. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1428.65, found 1428.3.
5. Synthesis of PEGA resin 11

5.1 Synthesis of Fmoc aminoxyacetic acid
In an ice-cooled round-bottomed flask, aminoxyacetic acid hydrochloride (500 mg, 4.58 mmol) was dissolved in water (20 mL). Sodium hydrogenocarbonate (1.15 g, 13.7 mmol) was dissolved in water (20 mL) and added to the aminoxyacetic acid solution. N-(9-Fluorenylmethoxycarbonyloxy)succinimide (1.70 g, 5.03 mmol) was dissolved in dioxane (60 mL) and added slowly to the above solution. After the addition, the ice-bath was removed and the reaction mixture was stirred at rt. After 4 hours, a first extraction with diethyl ether (100 mL) was performed. The aqueous phase (pH=8.4) was then acidified with 5 N HCl to pH 1 (a white precipitate forms). The mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried over anhydrous sodium sulfate during 30 min, filtered and evaporated to give 1.3 g (90.6%) of a yellow powder. Purification of the crude product (630 mg) by silica gel chromatography (DCM/AcOH 95/5 v/v by vol) yielded 330.6 mg (47.5%) of Fmoc aminoxyacetic acid.

5.2 Characterization of Fmoc aminoxyacetic acid
Figure S 36. $^1$H NMR spectrum (300.0 MHz, CDCl$_3$) of Fmoc aminoxayacetic acid.

5.3 Preparation of resin 11

*N*-succinimidyl Fmoc aminoxayacetate

In a round-bottomed flask, Fmoc aminoxacetic acid (93.94 mg, 0.299 mmol) and *N*-hydroxysuccinimide (34.79 mg, 0.302 mmol) were dissolved in dry dioxane/ethylacetate (1/1 v/v, 1 mL) and the reaction mixture was placed under inert atmosphere. The round-bottomed flask was placed on an ice bath and diisopropylcarbodiimide (47 µL, 0.3 mmol) was added dropwise. Then, the ice bath was removed and the reaction mixture was stirred at rt overnight. This solution was used directly in the next step.

Coupling of *N*-succinimidyl Fmoc aminoxayacetate to Rink PEGA resin

PEGA resin equipped with Rink linker (0.35 mmol/g, 24% in ethanol 1.19 g, 0.10 mmol) was washed with DMF (3 × 2 min). The solution of *N*-succinimidyl Fmoc aminoxayacetate (0.299 mmol) and *N*-methylmorpholine (16.5 µL, 0.15 mmol) were added to the resin. After 4 hours, the TNBS test showed the absence of free primary amino groups on the resin. Therefore, the solid support was washed with DMF (5 × 2 min), DCM (3 × 2 min) and absolute ethanol (3 × 2 min). The resin was stored swelled in absolute ethanol at 4°C. An aliquot was used to determine the loading of the resin by UV quantification (290 nm) of the dibenzofulvene-piperidine adduct produced by treating the resin with 20% piperidine in DMF (0.098 mmol/g in absolute ethanol).

6. Immobilization of AcA peptide 4b.

6.1 TFA cleavage leading to peptide 14b

The solid support prepared above (3.37 µmol) was washed with DMF (3 × 2 min). Fmoc protecting group was removed using 20% piperidine in DMF (2 × 2 min) to produce PEGA resin II. The solid support was washed with DMF (3 × 2 min), water (2 × 2 min) and 0.1 M sodium acetate buffer pH 4.4 (2 × 2 min). AcA peptide 4b (5.012 mg, 3.711 µmol) was dissolved in 0.1 M sodium acetate buffer pH 4.4 (260 µL) and added to PEGA resin II. The disappearance of AcA peptide 4b was monitored by RP-HPLC. After 48 h, the solid support was washed with water (4 × 2 min), DCM (3 × 2 min), diethyl ether (3 × 2 min) and dried under vacuum. The peptide was cleaved from the resin using TFA/water/thiophenol 95/2.5/2.5 for 1 h. The resin was drained and the cleavage repeated for 20 min using the same TFA cocktail. Precipitation of the peptide in diethylether/heptane 1/1 v/v furnished 1.7 mg of peptide 14b (35.5%).
6.2 Characterization of peptide 14b

Figure S 37. LC-MS analysis of peptide 14b. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1194.58, obs 1194.7.
Figure S 38. MALDI-TOF analysis of peptide 14b. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]\(^+\) calcd. (monoisotopic) 1194.58, found 1194.5.

7. Kinetic studies of the transoximation/rearrangement sequence: effect of the pH in the presence of aniline

A typical procedure is described for 20% AcOH, 0.1 M hydroxylamine, 0.5 M aniline, pH=4.3

Hydroxylamine (5.36 mg, 77.1 µmol) was dissolved in water (536.2 µL). Hydroxylamine solution (212.4 µL, 0.1 M final concentration), glacial acetic acid (61.12 µL, 20% final concentration) and aniline (13.94 µL, 0.5 M final concentration) were mixed together and the pH was adjusted to 4.3 by addition of 6 M NaOH (30 µL). This solution was added to oxime 10b (435 µg, 0.31 µmol) and the reaction mixture was stirred at 37 °C. The reaction was followed by RP-HPLC (column XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm) at 30 °C using a linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H\(_2\)O; eluent B = 0.1% TFA in CH\(_3\)CN/H\(_2\)O: 4/1 by vol). An aliquot of the reaction mixture (10 µL) was diluted with 40 µL of eluent A. 40 µL of this solution was injected.
Figure S 39. Influence of the pH on the transoximation and cleavage reaction in presence of 0.5 M aniline, 0.1 M H$_2$NOH, 20% AcOH, 37 °C.

Conclusion: the pH has no significant effect on the rate of cleavage in the presence of aniline.

8. Optimization of the cleavage protocol to minimize the formation of hydroxamic acid derivatives from Gln and Asn
We used for this study peptide C(SrBu)QPWSSMIPHEHSFLPSSYRGKDLQENY-SEA$^\text{off}$ which features two Gln residues.

8.1. Influence of the pH (cleavage method A at pH 4.3, 3.5 and 3.0)
Hydroxylamine (13.93 mg, 200.5 µmol) was dissolved in 20% AcOH (1.82 mL) and aniline (182.4 µL). Samples of this solution (1400 µL, 300 µL and 300 µL) were adjusted respectively at pH=3.03, pH=3.51 and pH=4.3 by addition of 6 M HCl (respectively 180 µL, 26 µL and 15 µL). These solutions (respectively 246.5 µL, 243.4 µL and 247.3 µL) were added to the peptide (respectively 1.014 mg, 1.001 mg and 1.017 mg) and the reaction mixtures were stirred at 45 °C under nitrogen. The appearance of +16 u side-products was monitored after 24 h by MALDI-TOF (matrix: sinapinic acid) and LC-MS (column XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm) at 30 °C using a linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H$_2$O; eluent B = 0.1% TFA in CH$_3$CN/H$_2$O: 4/1 by vol).

Table S 3. Effect of the pH on the level of +16 u impurities.

| MS technique | pH |
|--------------|----|
We conclude that lowering the pH from 4.3 to 3.0 results in a decrease in +16 u side-product formation.

### 8.2. Influence of additives: acetamide (cleavage method A at pH 3.0)

The above cleavage solution at pH 3.03 was used for this experiment. Acetamide (3.22 mg, 7.36 mg and 14.94 mg) was dissolved in the cleavage solution pH 3.03 (300 µL) to test the effect of acetamide (respectively 0.18 M, 0.41 M and 0.84 M final concentrations) on the level of +16 u side-product formation. The peptide (1.004 mg, 1.038 mg and 1.005 mg) was dissolved in respectively 244.09 µL, 252.4 µL and 244.34 µL of the above acetamide solutions and placed at 45 °C. The reaction was analyzed as described above after 24 h.

**Table S 4.** Effect of acetamide on the level of +16 u side-product formation (pH 3.03).

| MS technique | acetamide concentration |
|--------------|-------------------------|
|              | 0.18 M acetamide | 0.41 M acetamide | 0.84 M acetamide |
| LC-ESI MS    | 11.2%       | 16.2%       | 18.71%          |
| MALDI-TOF    | 6.1%        | 8.6%        | 18.6%           |

Conclusion: addition of acetamide increases the amount of +16 u side-product formation.

### 8.3. Influence of aniline concentration on the rate of cleavage

*A typical protocol is described using 20% AcOH, 0.1 M hydroxylamine and 2 M aniline at pH=3*

Hydroxylamine (5.18 mg, 74.5 µmol) was dissolved in water (51.82 µL). Hydroxylamine solution (22.6 µL, 0.1 M final concentration), glacial acetic acid (65.05 µL, 20% final concentration) and aniline (59.4 µL, 2 M final concentration) were mixed together and the pH=3 adjusted after addition of 6 M HCl (90 µL) and water (88.3 µL). This solution was used to dissolve oxime 10b (463 µg, 0.32 µmol). The reaction mixture was stirred at 45 °C. The reaction was monitored by RP-HPLC (column XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm) at 30 °C using a linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H₂O; eluent B = 0.1% TFA in CH₃CN/H₂O: 4/1 by vol) by diluting 10 µL of the reaction mixture in 40 µL of eluent A and injecting 20 µL.
Conclusion: the rate of cleavage is further increased by raising the concentration of aniline.

8.4. Influence of hydroxylamine concentration on the rate of cleavage

A typical protocol is described using 20% AcOH, 0.025 M hydroxylamine and 3 M aniline at pH=3

Hydroxylamine (2.69 mg, 38.7 µmol) was dissolved in water (53.74 µL). Hydroxylamine solution (11.45 µL, 0.025 M final concentration), glacial acetic acid (65.9 µL, 20% final concentration) and aniline (90.16 µL, 3 M final concentration) were mixed together and the pH adjusted to 3.0 after addition of 6 M HCl (125 µL) and water (37 µL). This solution was added used to dissolve oxime 10b (469 µg, 0.33 µmol). The reaction mixture was stirred at 45 °C. The reaction was monitored by RP-HPLC (column XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm) at 30 °C using a linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H₂O; eluent B = 0.1% TFA in CH₃CN/H₂O: 4/1 by vol) by diluting 10 µL of the reaction mixture in 40 µL of eluent A and injecting 20 µL.
Figure S 41. Influence of hydroxylamine concentration on the rate of cleavage (peptide 10b in solution).

9. Synthesis of ALKEPVHGA-SEA<sub>off</sub> peptide 15b

9.1 Cleavage method A

Oxime ligation on the solid support
Solid support 11 (5.55 µmol) was conditioned in 0.1 M sodium acetate buffer pH 4.4 (2 × 2 min) and drained. 2-hydroxy 5-methoxybenzoic acid (250 µg) was dissolved in 0.1 M sodium acetate buffer pH 4.4 (100 µL) and this solution was used to dissolve AcA peptide 4b (5.13 mg, 3.79 µmol). The peptide solution was added to the solid support and the suspension was agitated at 37 °C. The internal reference was used for monitoring the disappearance of AcA peptide 4b in solution by RP-HPLC. Conditions: XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm), 30 °C, linear gradient of 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H<sub>2</sub>O; eluent B = 0.1% TFA in CH<sub>3</sub>CN/H<sub>2</sub>O: 4/1 by vol).

Tandem transoximation/rearrangement reaction
After 48 h, the solid support was washed at room temperature with 0.1 M sodium acetate buffer pH 4.4 (3 × 2 min), water (4 × 2 min), 20% AcOH (2 × 2 min) and with the hydroxylamine solution (300 µL, 30 seconds, 0.1 M hydroxylamine, 1 M aniline, 6 M Gn.HCl, 20% AcOH, 14.9 mM 2-hydroxy 5-methoxybenzoic acid, pH 4.28).
Then, the solid support was drained and the hydroxylamine solution (300 µL) was added again to the beads which were agitated at 45 °C. The release of the peptide 15b in solution was quantified
by HPLC relative to the internal reference. Conditions: XBridge BEH300 C18 (3.5 µm, 300 Å, 4.6 × 150 mm), 30 °C, 0-100% of eluent B in eluent A over 30 min at a flow rate of 1 mL/min (eluent A = 0.1% TFA in H₂O; eluent B = 0.1% TFA in CH₃CN/H₂O: 4/1 by vol).

After 30 hours, the solid support was drained, washed with 20% AcOH (5 × 1 min, 3 mL) and water (5 × 1 min). The combined supernatants (final volume = 12 mL) were purified by HPLC to produce 4.3 mg of peptide 15b (82.2% for the two steps). Conditions: C18XBridge column, 0 to 10% eluent B in 5 min, then 10 to 50% eluent B in 120 min, eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 containing 0.1% TFA, rt, detection at 215 nm, 6 mL/min.

9.2 Characterization of peptide 15b (cleavage method A)

Figure S 42. LC-MS analysis of peptide 15b. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH₃CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 µm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]+ m/z calcd. (monoisotopic) 1038.52, obs 1038.9.
Figure S 43. MALDI-TOF analysis of peptide 15b. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1038.52, found 1038.4.

9.3 Cleavage method B

AcA peptide 4b (5.021 mg, 3.718 µmol) was dissolved in 0.1 M sodium acetate buffer pH 4.58 (100 µL containing 250 µg of 2-hydroxy 5-methoxybenzoic acid used as internal reference). This solution was added to solid support 11 (56.9 mg, 5.58 µmol). The oxime ligation on the solid support was monitored by RP-HPLC.

After completion of the ligation step, the solid support was washed with sodium acetate buffer pH 4.58 (3 × 2 min) and water (4 × 2 min), and with the cleavage solution (300 µL, 0.025 M hydroxylamine, 3 M aniline, 20% AcOH adjusted to pH 3.0). The solid support was then placed at 45 °C on a shaker. After 29 h, the solid support was drained and washed with buffer A (8 × 1 min, 5.7 mL). Purification by RP-HPLC (eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 containing 0.1% TFA, 30 °C, detection C18XBridge column) afforded 3.2 mg of peptide 15b (overall yield 63.7%).
Figure S 44. Comparison between cleavage methods A and B for peptidyl resin 12b. Cleavage method A: 20% AcOH, 0.1 M H₂NOH, 1 M aniline, pH 4.3, 45 °C; Cleavage method B: 20% AcOH, 0.025 M H₂NOH, 3 M aniline, pH 3.0, 45 °C.

9.4 Characterization of peptide 15b (cleavage method B)

Figure S 45. LC-MS analysis of peptide 15b. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH₃CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B
in 30 min (1 mL/min, detection 215 nm). MS trace. [M+H]$^+$ m/z calcd. (monoisotopic) 1038.52, obs 1038.8.

Figure S 46. MALDI-TOF analysis of peptide 15b. Matrix alpha cyano 4-hydroxycinnaminic acid, positive detection mode, [M+H]$^+$ calcd. (monoisotopic) 1038.52, found 1038.6.

10. Solid phase synthesis of peptide 17

10.1 Cleavage method A

Immobilization of AcA peptide 7

AcA peptide 7 (7.51 mg, 2.53 µmol) was dissolved in 0.1 M sodium acetate buffer pH 4.58 (150 µL containing 375 µg of 2-hydroxy 5-methoxybenzoic acid used as internal reference) and reacted with solid support 11 (38.3 mg, 3.75 µmol) as described before. The oxime ligation on the solid support was monitored by RP-HPLC. After 67 h, the solid support was washed with 0.1 M sodium acetate buffer pH 4.58 (3 × 2 min) and water (4 × 2 min).

Peptide elongation and cleavage

Peptide elongation was carried out using peptide segments C(SrBu)QPWSSMIPHEHSFLPSSYRGKDLQENY-SEA$^{off}$ and
CRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVK(Biotin)-NH$_2$. The synthesis of the peptide segments as well as the method used for the elongation have been described elsewhere.$^2$

At the end of the elongation, the solid support was washed with water ($10 \times 2 \text{ min}$), and quickly (30 seconds) with the cleavage solution (2 mL) at room temperature (0.1 M hydroxylamine, 1 M aniline, 6 M guanidinium hydrochloride, 20% AcOH, 2.24 mM internal reference 2-hydroxy 5-methoxybenzoic acid, pH 4.26). The cleavage solution was added again (2 mL) and the solid support was agitated at 45 °C. The release of the protein in solution was monitored by HPLC as described above.

After 29 hours, the solid support was drained and washed with 20% AcOH ($5 \times 1 \text{ min}$, 5 mL) and water ($5 \times 1 \text{ min}$, final volume = 20 mL). The supernatants were combined and extracted with diethyl ether to remove the internal reference prior to the HPLC purification (eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 containing 0.1% TFA, 30 °C, detection at 215 nm, 6 mL/min, 0 to 20% eluent B in 5 min, then 20 to 40% eluent B in 60 min, C18XBridge column). The purification furnished 7.9 mg of peptide 17 (overall yield 28%).

![Figure S 47. Immobilization of AcA-peptide 7 and cleavage of peptide 17 as monitored by HPLC using 2-hydroxy 5-methoxybenzoic acid as an internal reference.](image)

10.2 Characterization of peptide 17 (cleavage method A)
Figure S 48. LC-MS analysis of protein 17. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH₃CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 μm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace: [M+5H]⁵⁺ m/z calcd. 1922.97, obs. 1923.0, [M+6H]⁶⁺ m/z calcd. 1602.64, obs. 1603.0, [M+7H]⁷⁺ m/z calcd. 1373.84, obs. 1374.1, [M+8H]⁸⁺ m/z calcd. 1202.23, obs. 1202.4, [M+9H]⁹⁺ m/z calcd. 1068.76, obs. 1069.1, [M+10H]¹⁰⁺ m/z calcd. 961.99, obs. 962.0, [M+11H]¹¹⁺ m/z calcd. 874.62, obs. 873.7, [M+12H]¹²⁺ m/z calcd. 801.82, obs. 801.9.
Figure S 49. MALDI-TOF analysis of protein 17. Matrix sinapinic acid, positive detection mode, [M+H]$^+$ calcd. (mean) 9610.86, found 9609.6.
10.3 Cleavage method B

The peptidyl resin was prepared as described in the preceding section. At the end of the synthesis, the solid support was washed with water (10 × 2 min) and with the cleavage solution (2 mL, 0.025 M hydroxylamine, 3 M aniline, 20% AcOH adjusted to pH 3). The solid support was then placed at 45 °C on a shaker. After 4 h 20, the solid support was drained and the solution was frozen. A fresh solution (2 mL) was added to the solid support and the suspension was agitated for 5 h. The beads were drained and the supernatant frozen. The procedure was repeated twice after 14 h and 5 h 30.
At the end, the solid support was washed with eluent A (8 × 1 min, 4 mL). All the solutions were combined and purified by RP-HPLC (eluent A = water containing 0.1% TFA, eluent B=acetonitrile in water 4/1 containing 0.1% TFA, 30 °C, detection C18XBridge column) to afford 5.71 mg of peptide 17 (overall yield 21%).

10.4 Characterization of peptide 17 (cleavage method B)

A) Au (215 nm)

B)
Figure S 51. LC-MS analysis of protein 17. A) Crude protein 17 from cleavage solution (eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 XBridge BEH 300 Å 5 µm (4.6 × 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm); B) purified protein 17. LC trace, eluent C 0.10% FA in water, eluent D 0.10% FA in CH$_3$CN/water: 4/1 by vol. C3 Zorbax 300SB 3.5 µm (4.6 × 250 mm) column, gradient 0-100% D in 30 min (1 mL/min, detection 215 nm). MS trace: [M+6H]$^{6+}$ m/z calcd (mean) 1602.6, obs. 1603.2, [M+7H]$^{7+}$ m/z calcd. 1373.8, obs. 1373.9, [M+8H]$^{8+}$ m/z calcd. 1202.2, obs. 1202.5, [M+9H]$^{9+}$ m/z calcd. 1068.7, obs. 1069.0, [M+10H]$^{10+}$ m/z calcd.961.99, obs.962.2, [M+11H]$^{11+}$ m/z calcd. 874.6, obs. 874.9, [M+12H]$^{12+}$ m/z calcd. 801.8, obs. 800.4.
Figure S 52. MALDI-TOF analysis of protein 17. Matrix sinapinic acid, positive detection mode, [M+H]^+ calcd. (mean) 9610.86, found 9609.5.
Figure S 53. Deconvoluted spectrum for peptide 17 and comparison with the theoretical profile.

11. Solid phase synthesis of peptide 18 (cleavage method A)

The protocol used for preparing peptide 17a was applied to the synthesis of analog 18. The starting peptide Ac-AIRN-SEA\textsuperscript{off} 4e (1.99 mg, 2.52 µmol) was dissolved in 0.1 M sodium acetate buffer pH 4.58 (100 µL containing 250 µg of 2-hydroxy 5-methoxybenzoic acid used as internal reference) and reacted with solid support 11 (38.3 mg, 3.75 µmol). The oxime ligation on the solid support was followed as explained before by RP-HPLC.

After 22 h, the solid support was washed with 0.1 M sodium acetate buffer pH 4.58 (3 × 2 min) and water (4 × 2 min).

Peptide elongation was carried out using peptide segments C(SrBu)IIGKGRSYKGTVSITKSGIK-SEA\textsuperscript{off}, C(SrBu)QPWSSMIPHEHSFLPSSYRGKDLQENY-SEA\textsuperscript{off} and
At the end of the synthesis, the solid support was washed with water (10 \times 2 \text{ min}) and quickly with the cleavage solution (30 seconds, 2 mL) at room temperature (0.1 M hydroxylamine, 1 M aniline, 6 M G4.HCl, 20% AcOH, 2.15 mM 2-hydroxy 5-methoxybenzoic acid, pH 4.22). The solid support was drained and the cleavage solution was added again (2 mL). The suspension was then placed at 45 °C on a shaker.

After 29 hours, the solid support was drained. The solid support was washed with 20% AcOH (5 \times 1 \text{ min}, 5 \text{ mL}), water (5 \times 1 \text{ min}, final volume = 20 \text{ mL}). The supernatants were combined and extracted with diethyl ether to remove the internal reference prior to HPLC purification (eluent A = water containing 0.1% TFA, eluent B = acetonitrile in water 4/1 containing 0.1% TFA, 30 °C, detection at 215 nm, 6 mL/min, 0 to 20% eluent B in 5 min, then 20 to 40% eluent B in 60 min, C18XBridge column) which furnished 6.43 mg of peptide 18 (overall yield 23% starting from peptide segment 4e).

11.1 Characterization of protein 18 (cleavage method A)

\[ \text{CRNPRGE} \text{EV} \text{PCFTS} \text{NP} \text{EV} \text{RCV} \text{DIP} \text{C} \text{E} \text{V} \text{NH}_2. \]

Figure S 54. LC-MS analysis of protein 18. LC trace, eluent A 0.10% TFA in water, eluent B 0.10% TFA in CH$_3$CN/water: 4/1 by vol. C18 Xbridge BEH 300 Å 5 µm (4.6 \times 250 mm) column, gradient 0-100% B in 30 min (1 mL/min, detection 215 nm). MS trace: [M+5H]$^+$/m/z (mean) calcd. 1942.98, obs. 1943.9, [M+6H]$^+$/m/z calcd. 1619.3, obs. 1619.6, [M+7H]$^+$ m/z calcd. 1388.1, obs. 1388.3, [M+8H]$^+$ m/z calcd. 1214.74, obs. 1214.6, [M+9H]$^+$ m/z calcd. 1079.88, obs. 1080.0, [M+10H]$^{10+}$/m/z calcd. 971.99, obs. 972.6.
**Figure S 55.** MALDI-TOF analysis of protein 18. Matrix sinapinic acid, positive detection mode, [M+H]$^+$ calcd. (mean) 9710.92, found 9708.8.
11.2 Folding of peptide 18 into HGF K1 domain

Peptide 18 (5.85 mg, 0.52 µmol) was dissolved in pH 7.4 10 mM sodium phosphate buffer containing 138 mM NaCl, 2.7 mM KCl, 10% by vol of glycerol, 1 mM glutathione, 0.2 mM glutathione disulfide (total volume 17.3 mL).

The reaction mixture was placed at 4 °C. After 94 h, the reaction mixture was centrifuged at 4 °C at a relative centrifugal force (RCF) of 6000 during 15 minutes to eliminate the particles formed during the folding process.

The reaction mixture (~16.8 mL) was then concentrated by ultrafiltration (molecular weight cut-off of 3000, 12 °C, 12000 RCF). The solution was further dialysed 1 h then overnight at 4 °C in a dialysis cassette with a cut-off of 3500 against pH 7.4 10 mM sodium phosphate buffer containing 138 mM NaCl, 2.7 mM KCl, 10% by vol of glycerol (1 L). The volume was ~1.4 mL after dialysis.
The concentration of K1 domain 19 (144 µM) was determined using BCA assay and BSA as a reference.

11.3 Characterization of HGF K1 domain 19

![Intensity (light scattering, AU)](image)

Figure S 57. LC-MS analysis of protein 19. LC trace, eluent C 0.10% formic acid in water, eluent D 0.10% formic acid in CH$_3$CN/water: 4/1 by vol. Zorbax 300SB-C3 (3.5 µm, 300 Å, 4.6 × 150 mm) at 50 °C, gradient 0-50% D in 30 min (1 mL/min, detection 215 nm). MS trace: [M+6H]$^+$ m/z (mean) calcd. 1618.3, obs. 1618.3, [M+7H]$^+$ m/z calcd. 1387.27, obs. 1387.3, [M+8H]$^+$ m/z calcd. 1214.7, obs. 1214.1, [M+9H]$^+$ m/z calcd. 1079.2, obs. 1079.5, [M+10H]$^{10+}$ m/z calcd. 971.4, obs. 971.6, [M+11H]$^{11+}$ m/z calcd. 883.2, obs. 883.3, [M+12H]$^{12+}$ m/z calcd. 809.7, obs. 809.9.
Figure S 58. MALDI-TOF analysis of K1 protein 19. Matrix sinapinic acid, positive detection mode, [M+H]$^+$ calcd. (mean) 9704.92, found 9704.4.

11.4 Biological assays. K1 domain 19
MCF10A cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12 (1:1), Gibco® Life Technologies®) with 20 ng/mL human recombinant Epidermal Growth Factor (Peprotech®), 100 ng/mL cholera toxin (Calbiochem®), 0.01 mg/mL insulin (Sigma Aldrich®), 500 ng/mL hydrocortisone (Calbiochem®) supplemented with 5% horse serum (Life Technologies®). All media were supplemented with 1% Zell Shield™ (Minerva Biolabs®)
Recombinant human HGF/SF was purchased from Peprotech® (Rocky Hill, CT, USA).

Cells were cultured in 6-well plates and starved overnight in 0.1% SVF medium. They were then lysed with 100 µL RIPA buffer (20 mM HEPES, 1% NP40, 0.1% SDS, 5% glycerol, 142 mM KCl, 5 mM MgCl$_2$, 1 mM EDTA, pH 7.45) supplemented with phosphatase inhibitors (1/200
Phosphatase Inhibitor Cocktail 2 – Sigma® P5726) and protease inhibitors (1/400 Protease Inhibitor Cocktail – Sigma® P1860).

The total protein concentration was determined with the BCA Protein Assay Reagent Kit (Pierce®), and equal amounts of proteins were resolved on NuPAGE 4-12% Bis-Tris gels (Novex® by Life Technologies™). Separated proteins were transferred onto a polyvinyl difluoride membrane in Towbin buffer (10% methanol, 10% Tris-glycine 1X, 0.0025% SDS). The membrane was then equilibrated in blocking buffer (8 g casein/1L, PBS 1X, 0.2% Tween). Proteins were analyzed by western blotting with anti-phosphorylated MET at 1/1000 dilution from stock solution (Tyr 1234/1235, #3077 – Cell Signaling®) or anti-MET (3D4 - Life Technologies®). After incubation with the appropriate species-specific horseradish-peroxidase-conjugated secondary antibodies (anti-rabbit (#711-035-15), mouse (#115-035-146), or goat (#705-035-003) – Jackson ImmunoResearch Lab®), the antigen-antibody complexes were detected with a light-sensitive photographic film (CL-Xposure™ Film – Thermo Scientific®) after use of West Dura Extended Duration Substrate (SuperSignal®).

Figure S 59. MCF10A cells signaling analysis upon K1 stimulation. MCF10A cells were treated for 10 min with 500 pM mature HGF/SF (HGF), 1 µM K1 domain 19 and 1 µM K1B (see ref 3) used as a reference. Cell lysates were then analyzed by specific total MET or phospho-MET. Western blot. Ctrl: vehicle, MW: molecular weight.

11.5 Proteomic analysis of synthetic K1 domain 19

K1 domain 19 was dissolved in 25 mM ammonium bicarbonate pH 7.8 (1 mg/mL). This protein solution (10 µg of protein) was mixed with DTT (10 µg) and iodoacetamide (100 µg). After 30 min, trypsin solution in 25 mM ammonium bicarbonate (100 ng/µL) was added on the above solution and let at 37 °C overnight. The solution was directly spotted on a MALDI plate and mixed with alpha cyano 4-hydroxycinnaminic acid before analysis.
Figure S 60. MALDI-TOF spectrum generated fragments after reduction, alkylation and trypsin cleavage of K1 domain 19.
These data collected show that the +16 u modification is not located within the fragment 26-45 at m/z 2446.14 which contains the unique Met residue found in K1 domain 19 (no supplementary peak was observed at +16 u).

12. Total synthesis of biotinylated NK1 protein

12.1 One-pot synthesis of linear polypeptide NK1-B

Gdn.HCl (57.6 mg) was dissolved in 0.1 M phosphate buffer (60 µL) to give a final volume of 100 µL (6 M final concentration) and this solution was added to 4-mercaptophenylacetic acid (3.39 mg, 0.2 M final concentration). 6 M NaOH (7 µL) was added to adjust the pH to 6.98. Peptide 21 (1.07 mg, 0.22 µmol) was dissolved in the above solution (45 µL). After mixing, the solution was used to dissolve peptide 20 (2.25 mg, 0.22 µmol). The reaction was placed under inert atmosphere at 37 °C overnight.

After 26 h, Gdn.HCl (57.8 mg) was dissolved in 0.1 M phosphate buffer (60 µL) to give a final volume of 100 µL (6 M final concentration) and added to tris(2-carboxyethyl)phospine hydrochloride (5.78 mg, 0.2 M final concentration) and 4-mercaptophenylacetic acid (3.37 mg, 0.2 M final concentration). 6 M NaOH (13 µL) was added to adjust the pH to 5.22. Peptide 17 (2.49 mg, 0.22 µmol) was dissolved in this solution (45 µL) and added to the above reaction mixture (final pH 5.48). The reaction was placed under inert atmosphere at 37 °C.

After 40 h, the reaction mixture was diluted in 6 M Gdn.HCl (2 mL) and acidified with glacial acetic acid (200 µL). Three extractions with diethyl ether were done to remove 4-mercaptophenylacetic acid and the reaction mixture was further diluted with 6 M Gdn.HCl (2
mL) before RP-HPLC purification (eluent C = water containing 0.1% formic acid, eluent D=acetonitrile in water 4/1 containing 0.1% formic acid, 50°C, detection at 215 nm, 6 mL/min, 0 to 20% eluent D in 5 min, then 20 to 50% eluent D in 90 min, C3Zorbax column) which yielded 1.8 mg of protein NK1-B (35%).

A)

![Intensity (light scattering, AU)](image1)

B)

![Intensity (light scattering, AU)](image2)

**Figure S 62.** LC-MS analysis of peptide NK1-B. A) Crude one-pot mixture after MPAA extraction. B) Purified NK1-B polypeptide. LC trace, eluent C 0.10% FA in water, eluent D 0.10% FA in CH3CN by vol. C3 Zorbax 300SB 3.5 μm (4.6 × 250 mm) column, gradient 0-100% D in 30 min (1 mL/min, detection 215 nm). MS trace: M m/z calcd (mean) 20924.94, deconvoluted M 20926.79±2.51.
12.2 Folding of NK1-B polypeptide

NK1-B linear polypeptide (0.79 mg, 34.9 nmol) was dissolved in 10 mM PBS, 138 mM NaCl, 2.7 mM KCl buffer pH 7.4 containing 10 % by vol of glycerol, 1 mM reduced glutathione, 0.2 mM oxidized glutathione (1.176 mL). The reaction mixture was placed at 4°C.

The folding was monitored by LC-MS using a C3Zorbax 300 SB column (4.6 × 150 mm, 300 Å, 3.5 µm), 215 nm, 1 mL/min, 50°C, buffer C water containing 0.1 % formic acid, buffer D CH₃CN / water 4 / 1 containing 0.1 % formic acid, 0-100 % D in 30 min).

After 162 h, the reaction mixture was ultra-centrifuged at 6000 rcf and 12°C during 15 min to eliminate insoluble aggregates.

The mixture (876 µL) was then transferred in an ultrafiltration system (Vivaspin, 2 mL) with a cut-off of 3000 MWCO and ultrafiltered at 12000 rcf and 12°C during 45 min. Once concentrated (volume ~50 µL), the protein was diluted with 10 mM PBS, 138 mM NaCl, 2.7 mM KCl buffer pH 7.4 containing 10 % in vol of glycerol (100 µL) and then introduced in a dialysis cassette (cut-off of 3500 MWCO.)

Once dialysed twice (1 h then overnight) at 4°C against 10 mM PBS, 138 mM NaCl, 2.7 mM KCl buffer pH 7.4 containing 10 % in vol of glycerol (2 × 1 L), the volume was ~ 120 µL.

The concentration of the folded NK1-B protein was determined by measuring the absorbance at 280 nm with a Nanodrop system. Estimated concentration of NK1-B folded was 5.13 µM.

12.3 Biological activity

MCF10A or HeLA cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12 (1 :1), Gibco® Life Technologies®) with 20 ng/mL human recombinant Epidermal Growth Factor (Peprotech®), 100 ng/mL cholera toxin (Calbiochem®), 0.01 mg/mL insulin (Sigma Aldrich®), 500 ng/mL hydrocortisone (Calbiochem®) supplemented with 5% horse serum (Life Technologies®). All media were supplemented with 1% Zell Shield™ (Minerva Biolabs®)

Recombinant human HGF/SF was purchased from Peprotech® (Rocky Hill, CT, USA)

Cells were cultured in 6-well plates and starved overnight in 0,1% SVF medium. They were then lysed with 100 µL RIPA buffer (20 mM HEPES, 1% NP40, 0.1% SDS, 5% glycerol, 142 mM KCl, 5 mM MgCl₂, 1 mM EDTA, pH 7.45) supplemented with phosphatase inhibitors (1/200 Phosphatase Inhibitor Cocktail 2 – Sigma® P5726) and protease inhibitors (1/400 Protease Inhibitor Cocktail – Sigma® P1860).

The total protein concentration was determined with the BCA Protein Assay Reagent Kit (Pierce®), and equal amounts of proteins were resolved on NuPAGE 4-12% Bis-Tris gels (Novex® by Life Technologies™). Separated proteins were transferred onto a polyvinyl difluoride membrane in Towbin buffer (10% methanol, 10% Tris-glycine 1X, 0.0025% SDS). The membrane was then equilibrated in blocking buffer (8 g casein/1L, PBS 1X, 0.2% Tween).

Proteins were analyzed by western blotting with anti-phosphorylated MET at 1/1000 dilution from stock solution (Tyr 1234/1235, #3077 – Cell Signaling®), anti-MET (3D4 - Life Technologies®), anti-phosphorylated-AKT (Ser473, #9271 - Cell Signaling®), anti-AKT (Cell
Signaling®), anti-phosphorylated-ERK (Thr202/Tyr204, #9106 - Cell Signaling®), anti-ERK2 (C14 – Santa Cruz®). After incubation with the appropriate species-specific horseradish-peroxidase-conjugated secondary antibodies (anti-rabbit (#711-035-15), mouse (#115-035-146), or goat (#705-035-003) – Jackson ImmunoResearch Lab®), the antigen-antibody complexes were detected with a light-sensitive photographic film (CL-XposureTM Film – Thermo Scientific®) after use of West Dura Extended Duration Substrate (SuperSignal®).

![Western blot image](image)

**Figure S 63.** HeLa cells signaling analysis upon NK1-B stimulation. HeLa cells were treated for 10 min with 500 pM mature HGF/SF (HGF), NK1-B protein (50 and 100 nM). Cell lysates were then analyzed by specific total or phosphor MET, Erk or Akt antibodies. Western blot. Ctrl: vehicle, MW: molecular weight.

13. Peptide purification by covalent capture

13.1 Introduction

Bifunctional linkers described in previous studies (see Table 1 in the main manuscript) enabled also the purification of peptides produced by SPPS by setting up a solid phase covalent capture/release approach.\(^4,5\) Despite remarkable achievements, the previous solid phase approaches could not be applied to the isolation of peptide thioesters and/or \(O\)-acyl isopeptides which do not tolerate aqueous basic conditions. Peptide thioesters are key
components in the synthesis of proteins using NCL, while the incorporation of O-acyl isodipeptide units in a peptide backbone is a popular method to improve significantly the solid phase peptide synthesis (SPPS)\textsuperscript{6-8} and the solubility of hydrophobic peptides in aqueous solution.\textsuperscript{9-11}

We were particularly interested in the development of a covalent capture/release purification method that would be compatible with peptide segments featuring a protected N-terminal Cys residue, internal O-acyl isodipeptide units and a C-terminal thioester group. A solid phase method enabling the purification of such peptide segments should facilitate considerably the preparation of hydrophobic proteins.

Peptide 3f whose sequence is derived from AS-48 antimicrobial peptide was chosen as a model for this study. Preliminary attempts to produce the peptide with a natural backbone by classical Fmoc SPPS failed due to the high proportion of hydrophobic amino acids and the absence of charged residues in its sequence. The incorporation of three O-acyl isodipeptide units improved the synthesis and allowed the introduction of the AcA group after Fmoc SPPS (Scheme S 1).

![Scheme S 1. Synthesis of peptide 3f.](image)

The purification of the crude peptide was carried out as shown in Scheme S 2. First, the AcA peptide 3f was reacted with the aminooxyacetyl PEGA resin 11 at pH 3.0. At this pH, the O-acyl isopeptide units do not rearrange. This was confirmed by analysing the supernatant by HPLC which showed the stability of peptide 3f in these conditions. Importantly, this analysis showed also the selective capture of both SEA\textsuperscript{on} amide (X\textsubscript{1}) and thioester (X\textsubscript{2}) forms (see Figure S 64 below). The beads were thoroughly washed with 6 M Gn.HCl (pH 3) to remove the sticky impurities and then cleaved in TFA to produce peptide 24. In this peptide, the N-terminal Cys residue was protected by an N-acetoacetyloxime moiety while amide and thioester forms of the SEA group were present in equal proportion. The neutral amide form was further converted into the positively charged and hydrophilic thioester form by incubating the peptide in 6 M Gn.HCl pH 1.7. Peptide 25 which was equipped with a total of four positively charged amino groups and already separated from the main impurities by the solid phase capture step was further isolated by HPLC. Importantly, the structure of peptide 25 is confirmed by its MALDI-
TOF analysis which showed a typical fragmentation pattern due to the presence of the three O-acyl isopeptide bonds (see Figure S 69 and Figure S 70 below). This example demonstrates the usefulness of the method for accessing challenging peptides featuring base-sensitive O-acyl isopeptide and thioester functionalities.

Scheme S 2. Purification of peptide 3f by covalent capture.

13.2 Protocol and monitoring by LC-MS

Fmoc-aminoxyacetyl Rink PEGA resin (3.75 µmol) was washed with DMF (3 × 2 min). The Fmoc was removed by treatment with 20% piperidine/DMF v/v (2 × 2 min) and the solid support was washed with DMF (3 × 2 min), water (2 × 2 min) and 6 M Gn.HCl, 50 mM citrate buffer pH 3.0 (2 × 2 min). The crude peptide 4f (9.75 mg, 2.52 µmol) was dissolved in 6 M Gn.HCl, 50 mM citrate buffer pH 3.0 (500 µL) and added to the solid support. The bead suspension was shaken at 37 °C. The covalent capture of peptide 4f was followed by RP-HPLC.
The monitoring of the covalent capture shows the selective capture of peptide 4f, while impurities remained in solution. After 5 h 20, the solid support was thoroughly washed with 6 M Gdn.HCl, 50 mM citrate buffer pH 2.97 (10 × 2 min) then eluent A (10 × 2 min). The solid support was further washed with methanol (2 × 2 min) and dried under vacuum (15 min).

TFA cleavage was performed twice with TFA/water/triisopropylsilane/thiophenol 90/2.5/5/2.5 by volume during 1 h (2 × 400 µL). The cleaved peptide was precipitated in cold diethylether/heptane 1/1 by vol (8 mL), centrifuged, washed twice with cold diethylether/heptane 1/1 by vol and then dissolved in 6 M Gdn.HCl/eluent A pH 1.7. The peptide was immediately analyzed by LC-MS as shown in Figure S 64.
In order to isolate a unique species, the SEA\textsuperscript{on} amide form was rearranged in SEA thioester which has the advantage of being more hydrophilic. For this, the peptide solution in 6 M Gdn.HCl/eluent A pH 1.7 was agitated at rt for one day. LC-MS analysis of the crude mixture showed is shown in Figure S 65 and shows the presence of the thioester form as the major species.
The reaction mixture was diluted with 6 M Gdn.HCl/eluent A pH 1.7 (2 mL) and purified by RP-HPLC (eluent A = water containing 0.1% TFA, eluent B = acetonitrile in water 4/1 containing 0.1% TFA, 30 °C, detection at 215 nm, 6 mL/min, 20 to 50% eluent B in 90 min, then 50 to 70% eluent B in 20 min, C18XBridge column) to give 0.53 mg of peptide 24 (overall yield 6.6%).

13.2 Characterization of peptide 25
Figure S 67. LC MS of purified peptide 24. MS trace: [M+2H]$^{2+}$ m/z calcd. 1803.17, obs. 1803.2, [M+3H]$^{3+}$ m/z calcd. 1202.4, obs. 1202.4, [M+4H]$^{4+}$ m/z calcd. 902.1, obs. 902.2.
**Figure S 68.** MALDI-TOF analysis of peptide 25. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, \([M+H]^+\) calcd. (monoisotopic) 3602.9, found 3602.95.

**Figure S 69.** MALDI-TOF analysis of peptide 25. Matrix 2,5-dihydroxybenzoic acid (DHB), positive detection mode, focus on the ions produced by according a McLafferty rearrangement.
Figure S 70. Potential explanation for the fragmentation of peptide 25 at O-acyl isopeptide bonds.

14. References

(1) Boll, E.; Ebran, J. P.; Drobecq, H.; El-Mahdi, O.; Raibaut, L.; Ollivier, N.; Melnyk, O. Org. Lett. 2015, 17, 130-133.
(2) Raibaut, L.; Adihou, H.; Desmet, R.; Delmas, A. F.; Aucagne, V.; Melnyk, O. Chem. Sci. 2013, 4, 4061-4066.
(3) Simonneau, C.; Berenice, L.; Mougel, A.; Adriaenssens, E.; Paquet, C.; Raibaut, L.; Ollivier, N.; Drobecq, H.; Marcoux, J.; Cianferani, S.; Tulasne, D.; de Jonge, H.; Melnyk, O.; Vicogne, J. Chem. Sci. 2015, 6, 2110-2121.
(4) Canne, L. E.; Winston, R. L.; Kent, S. B. H. Tetrahedron Lett. 1997, 38, 3361-3364.
(5) Aucagne, V.; Valverde, I. E.; Marceau, P.; Galibert, M.; Dendane, N.; Delmas, A. F. Angew. Chem. Int. Ed. 2012, 51, 11320-11324.
(6) Sohma, Y.; Sasaki, M.; Hayashi, Y.; Kimura, T.; Kiso, Y. Chem. Commun. 2004, 124-125.
(7) Sohma, Y.; Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sasaki, M.; Kimura, T.; Kiso, Y. Biopolymers 2004, 76, 344-356.
(8) Coin, I.; Dölling, R.; Krause, E.; Bienert, M.; Beyermann, M.; Sferdean, C. D.; Carpino, L. A. J. Org. Chem. 2006, 71, 6171-6177.
(9) Sohma, Y.; Hayashi, Y.; Kimura, M.; Chiyomori, Y.; Taniguchi, A.; Sasaki, M.; Kimura, T.; Kiso, Y. J Pept Sci 2005, 11, 441-451.
(10) Sohma, Y.; Chiyomori, Y.; Kimura, M.; Fukao, F.; Taniguchi, A.; Hayashi, Y.; Kimura, T.; Kiso, Y. Bioorg Med Chem 2005, 13, 6167-6174.
(11) Carpino, L. A.; Krause, E.; Sferdean, C. D.; Schümman, M.; Fabian, H.; Bienert, M.; Beyermann, M. Tetrahedron Lett. 2004, 45, 7519-7523.